Want to see ORIC full AI Analyst Report?
Top Page
Oric Pharmaceuticals
(NASDAQ:ORIC)
Select Model
Select Model
Rating:52Neutral
Price Target:
$12.00
▲(11.63% Upside)
Action:Reiterated
Date:07/03/26
The score is primarily held back by weak financial performance: no revenue, widening losses, and worsening free cash flow indicate continued funding needs despite a low-debt balance sheet. Technicals are a positive tailwind with the stock trading above major moving averages and a positive MACD, but overbought readings add near-term risk. Valuation remains constrained by ongoing losses (negative P/E), while recent governance-related corporate actions provide only a modest positive influence.
Positive Factors
Low leverage / sizable equity base
The balance sheet shows zero reported debt and roughly $415.6M of equity. Low leverage materially reduces default and interest‑rate exposure and gives the company structural flexibility to fund R&D or pursue partnerships, supporting program continuity absent extreme cash shocks.
Negative Factors
No product revenue
The company has no product-derived revenue, consistent with a clinical-stage profile. This structural absence of a revenue base forces ongoing reliance on external financing and partner deals to sustain operations, leaving profitability and self-funding distant over the next several quarters.
Read all positive and negative factors
Positive Factors
Negative Factors
Low leverage / sizable equity base
The balance sheet shows zero reported debt and roughly $415.6M of equity. Low leverage materially reduces default and interest‑rate exposure and gives the company structural flexibility to fund R&D or pursue partnerships, supporting program continuity absent extreme cash shocks.
Read all positive factors
Oric Pharmaceuticals (ORIC) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$878.86M
Dividend YieldN/A
Average Volume (3M)1.67M
Price to Earnings (P/E)―
Beta (1Y)1.25
Revenue GrowthN/A
EPS Growth23.91%
CountryUS
Employees122
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.44
Shares Outstanding103,517,560
10 Day Avg. Volume1,714,182
30 Day Avg. Volume1,674,520
Financial Highlights & Ratios
PEG Ratio0.28
Price to Book (P/B)1.87
Price to Sales (P/S)0.00
P/FCF Ratio-6.30
Enterprise Value/Market Cap0.96
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-2.63K
Enterprise Value/Ebitda-6.27
Forecast
1Y Price Target
$19.67Price Target Upside82.95% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
EPS Forecast (FY)-1.45
Revenue Forecast (FY)N/A
Oric Pharmaceuticals Business Overview & Revenue Model
Company Description
ORIC Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm dedicated to discovering and advancing innovative treatments for cancer patients across the United States. The company's pipeline includes several key clinical-stage dr...
How the Company Makes Money
ORIC does not have publicly disclosed recurring revenue from marketed products; as a clinical-stage company, it primarily finances operations through capital raising activities rather than product revenue. Its cash inflows have historically been g...
Oric Pharmaceuticals Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
63
Positive
Cash Flow
25
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -320.00K | -1.22M | -1.11M | -1.03M | 0.00 | 0.00 |
| EBITDA | -134.03M | -128.25M | -126.74M | -99.67M | -85.80M | -77.82M |
| Net Income | -135.21M | -129.47M | -127.85M | -100.70M | -89.12M | -78.72M |
Balance Sheet | ||||||
| Total Assets | 436.76M | 411.00M | 274.14M | 254.69M | 250.36M | 298.64M |
| Cash, Cash Equivalents and Short-Term Investments | 281.93M | 281.49M | 255.96M | 208.19M | 206.27M | 236.98M |
| Total Debt | 3.30M | 11.55M | 3.18M | 10.21M | 12.10M | 1.93M |
| Total Liabilities | 21.20M | 26.64M | 31.02M | 30.60M | 28.01M | 25.67M |
| Stockholders Equity | 415.56M | 384.36M | 243.12M | 224.09M | 222.35M | 272.98M |
Cash Flow | ||||||
| Free Cash Flow | -111.36M | -114.08M | -113.85M | -86.54M | -77.22M | -60.48M |
| Operating Cash Flow | -110.88M | -113.37M | -112.66M | -85.69M | -75.14M | -59.54M |
| Investing Cash Flow | -188.46M | -148.03M | 22.14M | -43.40M | -109.25M | 158.44M |
| Financing Cash Flow | 306.39M | 245.26M | 126.55M | 85.66M | 25.23M | 49.13M |
Oric Pharmaceuticals Technical Analysis
Positive
10.75
Price Trends
8.95
Positive
10.15
Positive
10.67
Positive
Market Momentum
0.60
Negative
77.81
Negative
94.38
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ORIC, the sentiment is Positive. The current price of 10.75 is above the 20-day moving average (MA) of 8.91, above the 50-day MA of 8.95, and above the 200-day MA of 10.67, indicating a bullish trend. The MACD of 0.60 indicates Negative momentum. The RSI at 77.81 is Negative, neither overbought nor oversold. The STOCH value of 94.38 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ORIC.
Oric Pharmaceuticals Risk Analysis
Oric Pharmaceuticals disclosed 98 risk factors in its most recent earnings report. Oric Pharmaceuticals reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Oric Pharmaceuticals Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
62 Neutral | $7.52B | -39.74 | -31.25% | ― | ― | 22.31% | |
59 Neutral | $2.55B | -55.65 | -24.53% | ― | ― | 27.89% | |
56 Neutral | $8.88B | -23.79 | -43.02% | ― | -100.00% | -24.90% | |
56 Neutral | $992.01M | 71.34 | 4.75% | ― | 15.66% | ― | |
52 Neutral | $878.86M | ― | -35.33% | ― | ― | 23.91% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
45 Neutral | $698.99M | -3.05 | -188.82% | ― | 4.89% | 24.20% |
* Healthcare Sector Average
ORIC
Oric Pharmaceuticals
11.64
0.99
9.30%
SYRE
Spyre Therapeutics
86.63
71.33
466.21%
TRVI
Trevi Therapeutics
17.93
11.98
201.34%
PRAX
Praxis Precision Medicines
318.52
271.84
582.35%
PHAR
Pharming Group
13.77
3.89
39.37%
PRME
Prime Medicine, Inc.
3.87
0.07
1.84%
Oric Pharmaceuticals Corporate Events
Business Operations and StrategyExecutive/Board ChangesShareholder Meetings
Oric Shareholders Approve Equity Plan, Governance Measures
Positive
Jun 22, 2026
On June 18, 2026, ORIC Pharmaceuticals’ shareholders approved an amended and restated 2020 Equity Incentive Plan that adjusts its evergreen feature, caps incentive stock option issuances at 10 million shares within the plan’s reserve, ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.